Compugen Ltd. Reports First Quarter 2012 Financial Results|May 01, 2012
Non-cash Baize arrangements charges added significantly to loss for quarter
Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001|Apr 24, 2012
CGEN-15031 and CGEN-15051 demonstrate therapeutic potential in animal models of autoimmune diseases. Further results substantiate CGEN-15001's immunomodulatory activity and potential for additional utility in the treatment of inflammatory bowel diseases.
Compugen Establishes Operations in California for Development of Monoclonal Antibody Drug Candidates|Mar 28, 2012
Dr. Mary Haak-Frendscho and Dr. John J. Hunter to lead new operations Drug candidates to be developed against Compugen-discovered targets